Disc Medicine (IRON) shares surge over 70% on positive Phase 3 trial
FROM THE WIRE · GURUFOCUS.COM
On October 19, 2026, Disc Medicine Inc (NASDAQ: IRON) saw its stock price soar over 70% following the announcement of positive Phase 3 trial results for its lea
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishSharp move in a small-cap biotech stock after positive Phase 3 data.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Disc Medicine shares rose over 70%.
- 02The rise follows an announcement of positive Phase 3 trial results.
- 03The trial concerns the drug bitopertin.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets